From the Laboratory of Molecular Structure and
Functions, Department of Molecular Biology, Institute of Molecular and
Cellular Biosciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku,
Tokyo 113-0032, Japan, ¶ Généthon, 1, Rue de
L'internationale, 91000 Evry, France, and the
Department of
Molecular Biology, Tokyo Metropolitan Institute of Medical Science,
3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-0021, Japan
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
p94 (calpain3), a muscle-specific member of the calpain family, has been shown to be responsible for limb-girdle muscular dystrophy type 2A (LGMD2A), a form of autosomal recessive and progressive neuromuscular disorder. To elucidate the molecular mechanism of LGMD2A, we constructed nine p94 missense point mutants found in LGMD2A and analyzed their p94 unique properties. All mutants completely or almost completely lose the proteolytic activity against a potential substrate, fodrin. However, some of the mutants still possess autolytic activity and/or connectin/titin binding ability, indicating these properties are not necessary for the LGMD2A phenotypes. These results provide strong evidence that LGMD2A results from the loss of proteolysis of substrates by p94, suggesting a novel molecular mechanism leading to muscular dystrophies.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Calpain (EC 3.4.22.17), Ca2+-dependent cysteine protease, is a major intracellular protease thought to regulate the cellular function by hydrolyzing substrates in a highly limited manner (1). Previously identified µ- and m-calpains exist as heterodimers consisting of a unique large catalytic subunit and a common small regulatory subunit. The large subunit can be divided into four structural domains; the second and the fourth domains (domains II and IV) are cysteine protease and Ca2+ binding domains, respectively. The small subunit is composed of an NH2-terminal Gly-rich hydrophobic region (domain V) and a Ca2+ binding domain similar to domain IV of the large subunit (domain IV' or VI).
In addition to these two species, which are ubiquitously expressed in almost all mammalian tissues, several novel species of the calpain large subunit family expressed in a tissue-specific manner have been cloned (2, 3). Thus, it is now established that calpains, at least in mammals, can be classified into two groups, ubiquitous and tissue-specific species, and that the latter should have tissue-specific functions that cannot be accomplished by the former.
p94 (calpain 3 or nCL-1, which stands for novel calpain large subunit) is a muscle-specific member of the calpain large subunit family (2, 4). p94 is expressed predominantly in skeletal muscle where mRNA for p94 is at least 10 times more abundant than those for the µ- and m-calpain large subunits. p94 has three specific insertion sequences, NS, IS1, and IS2. Contributions of these sequences, especially IS2 which includes a nuclear translocation signal, to p94 specific function are presumed.
The recent discovery that the p94 gene is responsible for limb-girdle muscular dystrophy type 2A (LGMD2A)1 supports the idea that p94-specific function is indispensable for normal muscular function (5). LGMD2A is a form of autosomal recessive LGMD, a genetically heterogeneous group of inherited progressive neuromuscular disorders (6, 7). In LGMD2C, -2D, -2E, and -2F, a deficiency in one of the sarcoglycan molecules results in the down-regulation of the whole sarcoglycan complex and the subsequent destabilization of membrane structure (8-13). This is consistent with the fact that deficiencies in structural proteins around the sarcolemma are commonly observed in all muscular dystrophies so far identified except LGMD2A (14).
To investigate the correlation between p94 function and LGMD2A pathology, we tried to evaluate the effects of p94 mutation in LGMD2A focusing on the following p94-specific features, which suggest its pivotal role in protein turnover and/or in function of muscle. First, although p94 is expressed abundantly at the mRNA level in skeletal muscle, little is detectable as protein because of its very rapid autolysis. Moreover, p94 autolyzes even in the presence of excess EGTA, E-64, leupeptin, or calpastatin, a specific proteinaceous inhibitor of conventional calpain (4). This rapid and complete autolysis discriminates p94 from other cysteine proteases including calpains. Second, p94 associates with connectin/titin. Connectin/titin is a gigantic muscle protein in charge of muscle elasticity and structure of myofibrils (15-17). Using the yeast two-hybrid system, we found that p94 binds to the C terminus and the N2A region of connectin/titin (18), suggesting the regulation mechanism of p94 function and myofibril turnover (19).
In this study, we report that all the p94 point mutants found in LGMD2A examined so far completely or almost completely lose the fodrin proteolysis activity and that all the mutants show changes in autolytic activity and/or connectin/titin binding activity. These results indicate that the loss of p94 protease activity rather than its autolytic activity underlies the molecular mechanism of LGMD2A.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasmid Construction and Site-directed Mutagenesis-- Wild type human p94 cDNA was constructed into pSRD or pAS2-1 (20-22) for protein expression. Polymerase chain reaction-based mutagenesis using long polymerase chain reaction was employed to create an active site mutation, C129S, and the point mutations found in LGMD2A, L182Q, G234E, P319L, H334Q, V354G, R490W, R572Q, S744G, and R769Q in wild type human p94 cDNA (23). Briefly, sense and antisense primers used to create each amino acid substitution were designed to introduce a diagnostic restriction site at the same time. Each mutant was sequenced to verify the presence of the mutation and the absence of any other alterations. Two clones of human connectin/titin cDNA, pCNT-N2 and pCNT-52, identified as positive for p94 binding in our previous study (18), were subcloned into pACT2 and pGAD10 vectors for binding assay by the yeast two-hybrid system.
Expression in COS7 Cells-- COS7 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Transfection was performed by electroporation using a Bio-Rad gene pulser as described previously (24) with 5 µg of each expression vector cDNA or the same amount of pSRD vector and 5 × 106 COS7 cells. For the coexpression experiment, 5 × 106 COS7 cells were transfected by the mixture of expression vector for C129S and that for wild type or mutant p94. The following procedures were carried out within 10 min (from the cell scrape to the addition of SDS) at 0-4° C. 60 h after transfection, the cells were washed three times with phosphate-buffered saline, scraped in phosphate-buffered saline, collected in an ice-cold 1.5-ml tube within 1 min after the scrape of cells. Cells were collected by centrifugation at 4,000 rpm for 2 min, and disrupted by sonication in buffer A (100 mM Tris-HCl, pH 7.5, 10 mM EDTA, 1 mM dithiothreitol). An equal volume of SDS-polyacrylamide gel electrophoresis sample buffer (100 mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.4% (w/v) bromphenol blue, 5% (v/v) 2-mercaptoethanol) was added to the cell extracts immediately after disruption. For the incubation assay, one-third volume of 10 mM EDTA or 50 mM CaCl2 was added to cell extracts prepared as above. Incubation was carried out at 37° C, and the reaction was stopped by adding an equal volume of SDS-polyacrylamide gel electrophoresis sample buffer.
Antipeptide Antisera--
The p94-specific anti-IS2 antiserum
was produced using the Lys-rich peptide corresponding to the
NH2-terminal Lys-rich sequence of the IS2 region. This
antiserum is identical to the anti-K-rich antiserum in our previous
report (4). The antibody specific for the proteolyzed 150-kDa form of
the fodrin subunit was raised against the 5-mer peptide, GMMPR,
corresponding to the NH2-terminal sequence of the
calpain-catalyzed proteolytic fragment (25).
Western Blotting-- Whole cell extracts prepared as described above were fractionated by SDS-polyacrylamide gel electrophoresis in 10 or 6% gels. Sample volumes were normalized according to cell number. Proteins were transferred onto polyvinylidene difluoride membranes (Immobilon P, Millipore, Japan) as recommended by the supplier and incubated with specific antisera as indicated. The secondary antibody was horseradish peroxidase-coupled goat anti-rabbit IgG (Vector Laboratories, Inc., U.S.A.). The antibody complexes were visualized using peroxidase substrate (PODTM immunostaining set, Wako, Japan).
Binding Assay by the Yeast Two-hybrid System--
Wild type and
mutant human p94 in pAS2-1, and pCNT-N2 and pCNT-52 human
connectin/titin cDNAs in pACT2 and pGAD10 vectors, respectively,
were coexpressed in CG-1945 strain Saccharomyces cerevisiae
as described by the manufacturer (MATCHMAKERTM Two-Hybrid
System, CLONTECH, U.S.A.). Binding was assayed as growth on Leu,Trp,His plates supplemented with 1.5, 5, or 15 mM 3-amino-1,2,4-triazole and by
-galactosidase activity
using chlorophenol red-
-D-galactopyranoside as a
substrate essentially as described previously (18).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Connectin/titin Binding Activity of Point Mutants-- As shown in Fig. 1, various point mutations of p94 have been identified in LGMD2A patients (5, 26), and these are expected to abolish one or two but not all of various p94 characteristics described in the Introduction. To clarify which p94 properties is most related to LGMD2A, we constructed 9 of these missense mutations, L182Q, G234E, P319L, H334Q, and V354G in domain II, R490W and R572Q in domain III, and S744G and R769Q in domain IV by site-directed mutagenesis.
|
|
Expression of Point Mutants Found in LGMD2A in COS7 Cells-- To examine whether LGMD2A arises from the loss of p94 autolytic activity, we used a COS expression system previously described (4). In this system, wild type p94 is hardly detected as a 94-kDa band because of its rapid autolysis but, instead, as a 55-kDa autolyzed product, whereas an active-site mutated inactive p94, C129S, is clearly detected as a stable 94-kDa translated product (Fig. 3, lanes 2 and 3). Thus, it is concluded that p94 is degraded by itself but not by other endogenous proteases in COS7 cells as we previously reported (4).
|
Reduced Autolytic Activity by the Mutations R490W and R572Q-- It looks strange that R572Q mutant, whose mutation localizes in domain III not in the protease domain, showed severely reduced autolytic activity. To clarify the mechanism of the reduction of activity by mutation of domain III, autolysis profiles of R572Q as well as R490W were examined in detail in comparison with wild type and C129S. As our previous studies showed (4), wild type p94 expressed in COS7 cells continues to degrade autocatalytically in the presence of 10 mM EDTA (Fig. 4A). That is, the 55-kDa fragment of wild type p94 disappeared depending on time (Fig. 4A, wild type, lanes 1-4). A similar degradation of the 55-kDa fragment was observed in the presence of Ca2+ (Fig. 4B, wild type, lanes 1-4). These results showed apparent Ca2+-independent autolytic activity of wild type p94. On the other hand, the 94-kDa product of C129S does not undergo remarkable degradation in the presence of EDTA or Ca2+ (Figs. 4, A and B, C129S, lanes 1-4), indicating that endogenous proteases can be ignored in this system.
|
Enhanced Autolytic Activity by the Mutations in Domain IV, S744G and R769Q-- To further confirm the existence of the proteolytic activity of S744G and R769Q, intermolecular C129S p94 processing activity was examined by coexpression of these mutants with C129S. Wild type p94 has been shown to proteolyze other C129S p94 molecules when coexpressed with C129S in COS7 cells as previously reported (18). When C129S and wild type p94 were coexpressed in COS7 cells and extract of the cells cultured for 60 h were immediately subjected to Western blotting without further incubation, intermolecular cleavage of C129S and production of the 55-kDa proteolyzed fragment were detected by anti-IS2 antiserum (Fig. 5, lane 3).
|
Deficient Proteolysis of the Fodrin Subunit--
In contrast
to our expectations, the nine missense mutants examined showed diverged
properties concerning autolytic activity and connectin/titin binding
ability as discussed below, although none had properties identical to
those of the wild type. This is apparently contradictory to the fact
that all nine mutations result in a common phenotype. To seek a
property that is altered in all nine mutants, we further analyzed the
protease activity of p94 against possible substrates.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this study, we examined the properties of p94 point mutants found in LGMD2A (5, 26), and identified a complete or nearly complete loss of in vivo fodrinolysis as a common property of these nine mutants. None of the mutants were identical to wild type p94 as summarized in Table I. Namely, all mutants show a deficiency in autolytic activity and/or binding ability to the N2A and/or C-terminal regions of connectin/titin. Based on the fact that only COS7 cells transfected with wild type human p94 produce substantial amounts of the 150-kDa proteolyzed fodrin fragment, proteolysis of p94 substrates, if not fodrin, is certainly altered in all mutants.
|
The involvement of p94 activity in the proteolysis of fodrin observed in our experiments is either direct or indirect. If p94 cleaves fodrin in the same manner as µ- and m-calpains (25), the complete or nearly complete loss of this proteolysis observed for all mutants provides direct evidence that insufficient proteolytic reaction mediated by p94 causes LGMD2A. Alternatively, p94 may regulate fodrinolysis indirectly, i.e. proteolysis of unidentified p94 substrates finally results in the activation of endogenous calpain(s), possibly m-calpain in COS7 cells. In this case, the reduction in the amount of final product, the 150-kDa fragment, can be attributed to a defect in the step catalyzed by p94. Either case is consistent with the idea that a loss of proper protease function is a mechanism for the etiology of LGMD2A, which has been proposed from the existence of mutant species lacking the protease domain.
Our results provide evidence that unique characteristics of p94 distinct from ordinary calpain are functionary important. Our finding that R490W and R572Q can autolyze efficiently only in the presence of Ca2+ emphasizes that p94 is active without Ca2+ or at very low concentrations such as the sub nanomolar level. It is interesting that these mutations in domain III, not IV, altered Ca2+ requirement of p94. Mutagenesis of Asp104 adjacent to the active site Cys105 has been reported to cause a 9-fold increase in the Ca2+ requirement (29). Thus, the Ca2+ requirement of calpain is determined not only by Ca2+ binding domain IV but also by the whole structure including domains I, II, and III.
Autolysis of p94 is rapid and exhaustive but under a certain
regulation. The fact that S744G and R769Q autolyze even more rapidly
than wild type p94, but cannot catalyze in vivo fodrinolysis as efficiently as wild type p94, means that a too rapid autolysis causes functional defect. This is not unrelated to structural changes
in the EF-hands of the Ca2+ binding domain. Recently, the
crystal structure of domain IV' (VI) of the calpain small subunit,
which is similar to domain IV of the large subunit, has been determined
(30, 31). The result shows the existence of five, rather than four
EF-hands previously predicted, and reveals that the extreme C-terminal EF-hand structure is involved in the homodimer formation of domain VI.
Ser744 and Arg769 corresponding to
Ser189 and Arg214 of the small subunit,
respectively, are located at the boundary of the -helix and
Ca2+ binding loop of EF-3 (Ser744) and EF-4
(Arg769). Thus, it is likely that the S744G or R769Q
mutations cause changes in the structure and/or Ca2+
binding affinity of EF-3 and EF-4, resulting in the hyperactivation of
p94. We have shown that p94 does not associate with the small subunit
under the conditions where the large subunits of µ- and m-calpain
show association with the small subunit (18). The above observation
suggests that, although p94 shows apparent Ca2+-independent
protease activity in vitro, Ca2+ ions play an
important role in the regulation of p94 activity, presumably at very
low concentrations such as the sub nanomolar level.
Further investigation is required as to how the interaction between p94 and connectin/titin is involved in LGMD2A. We have found no common alteration in connectin/titin binding ability among the nine mutants so far examined. Although the result might indicate that connectin/titin binding has nothing to do with LGMD2A, it does not necessarily exclude physiological importance of an association between p94 and connectin/titin. p94 is known to bind to the Z-line of myofibril other than the N2A and the C-terminal regions, although we have not yet identified the binding site at the molecular level (18). It is therefore, possible that mutant p94 cannot bind to the Z-line. Moreover, because the two p94 binding sites of connectin/titin, N2A and C terminus, are produced by alternative splicing, alternative splicing might regulate the interaction between p94 and connectin/titins (32, 33).
From the viewpoint of molecular mechanism underlying the disease, it is noteworthy that p94, a responsible gene product for LGMD2A, is not a membrane or cytoskeletal component as are the products of the genes responsible for other muscular dystrophies, including LGMD2C-2F. Studies using antisense oligodeoxyribonucleotides showed the involvement of p94 in myofibrillar integrity (34), and thus defects in p94 might cause high susceptibility of the sarcolemma to stress by disturbing proper myogenesis or myodifferentiation. The present work together with the further characterization of p94 function will provide a clear definition and reveal the molecular mechanism of LGMD2A (35-38).
![]() |
FOOTNOTES |
---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 81-3-3812-2111 (ext. 7821); Fax: 81-3-3813-0654; E-mail: sorimach{at}iam.u-tokyo.ac.jp.
1 The abbreviation used is: LGMD2A, limb-girdle muscular dystrophy type 2A.
2 K. Kinbara, S. Ishiura, S. Tomioka, M. Sorimachi, S. Y. Jeong, S. Amano, H. Kawasaki, B. Kolmerer, S. Kimura, S. Labeit, and K. Suzuki, manuscript in preparation.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|